Advances in Bladder Cancer: Innovation in Diagnostics, Therapeutic Technology, and Clinical Pathways

Non–muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) continue to pose significant clinical and health-economic challenges in urology. Despite advances in early diagnosis and management, NMIBC is characterized by high rates of recurrence, the need for long-term surveillance, and an expanding and increasingly complex therapeutic landscape. In parallel, management of MIBC is evolving through improvements in perioperative pathways and systemic strategies, yet outcomes remain heterogeneous and resource-intensive.Recent years have seen the introduction of enhanced cystoscopic imaging, artificial intelligence (AI)-assisted detection methods, and emerging urinary biomarkers, each showing promise for earlier detection, improved risk stratification, and better selection of patients for intensified therapy. At the same time, molecular subtyping and genomic profiling are reshaping how clinicians and researchers conceptualize disease biology across NMIBC and MIBC, opening the door to precision medicine approaches and more individualized treatment pathways. However, questions persist regarding the comparative effectiveness of these innovations in routine clinical practice, how best to integrate molecular profiling and predictive biomarkers into decision-making, and which endpoints most meaningfully capture clinical benefit beyond traditional recurrence and survival metrics.Therapeutic innovation is also accelerating. Novel intravesical agents and drug delivery platforms, evolving systemic regimens, and innovations in immunotherapy, including next-generation intravesical immunotherapies and rational combination strategies, are expanding options across disease stages. This creates an urgent need for predictive biomarkers that can guide selection among intravesical, systemic, and combination therapies, reduce overtreatment, and identify patients most likely to benefit. In addition, adaptive clinical trial designs, real-world evidence generation, and novel clinical endpoints are increasingly necessary to evaluate fast-moving technologies and treatment combinations efficiently, while ensuring generalizability across diverse healthcare settings.Crucially, not all patients benefit equally from technological and therapeutic advances. Disparities in access, variation in implementation, and the burden of chronic surveillance highlight the importance of patient-centered care models. Patient-reported outcomes (PROs), digital symptom monitoring, and survivorship-focused pathways are essential to understanding real-world impact on quality of life, treatment tolerability, and long-term wellbeing, while also informing value-based care and resource utilization.This Research Topic aims to gather high-quality contributions addressing multi-faceted approaches to bladder cancer management, emphasizing innovation and technology that improve outcomes while maintaining cost-effectiveness and equity. We welcome multidisciplinary work spanning diagnostics, molecular profiling, therapeutic innovation, trial methodology, real-world implementation, and patient-centered care. The Research Topic will not cover non-urological malignancies.- Diagnostic innovation in bladder cancer: enhanced imaging, AI, urinary biomarkers, and comparative effectiveness in real-world practice- Molecular subtyping, genomic profiling, and precision medicine approaches in NMIBC and MIBC- Predictive biomarkers for response to intravesical, systemic, and combination therapies- Innovations in intravesical therapy and novel drug delivery, including emerging agents and platforms- Immunotherapy innovation: novel intravesical immunotherapies and combinatorial strategies across disease stages- Perioperative care, surveillance strategies, and digital health integration (risk-adapted pathways, monitoring, workflow redesign)- Adaptive clinical trial designs, real-world evidence generation, and novel clinical endpoints relevant to bladder cancer innovation- Patient-reported outcomes measures (PROMS), digital symptom monitoring, and survivorship-focused care models- Health economic analyses and resource utilization models, including value-based evaluations of new diagnostics/therapies- Novel technologies, instrument design & evaluation- Implementation science, adoption frameworks, and equity-focused strategies to scale innovation across populations and settingsProf. Sachin Agrawal reports advisory and educational engagements with Biolitec, Promed, Photocure, and Ambu. Miss Helena Burden declares consultancy for Olympus and paid honoraria/advisory board participation for Medac, Promed, Stor, Olympus, AstraZeneca, Photocure, and Pfizer. Topic editors: Sachin Agrawal, Professor Nikhil Vasdev, Helena Burden Source: https://www.frontiersin.org/research-topics/76723/advances-in-bladder-cancer-innovation-in-diagnostics-therapeutic-technology-and-clinical-pathways